Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 12/20 | 0.36 |
| ▸ | ATP4A | P20648 | 1/20 | 0.35 |
| ▸ | ATP4B | P51164 | 1/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 4/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664655 | 1.00 | RAB9A (0.36) | RAB9ARIPK1BRD4ATP4AATP4B | |
| SCHEMBL4663231 | 0.91 | LIPG (0.39) | RAB9ARIPK1BRD4SLC8A1 | |
| SCHEMBL4663178 | 0.90 | DHODH (0.36) | RAB9AATP4AATP4BSLC8A1 | |
| SCHEMBL6020045 | 0.90 | DHODH (0.36) | RAB9AATP4AATP4BSLC8A1 | |
| SCHEMBL6019450 | 0.90 | DHODH (0.36) | RAB9AATP4AATP4BSLC8A1 | |
| SCHEMBL4965120 | 0.89 | BRD4 (0.35) | BRD4SLC8A1 | |
| SCHEMBL5511615 | 0.89 | ATP4A (0.33) | RAB9AATP4AATP4B | |
| SCHEMBL5506543 | 0.88 | RAB9A (0.35) | RAB9AATP4AATP4BSLC8A1 | |
| SCHEMBL4666543 | 0.88 | RAB9A (0.35) | RAB9AATP4AATP4BSLC8A1 | |
| SCHEMBL5506550 | 0.88 | RAB9A (0.35) | RAB9AATP4AATP4BSLC8A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | claimed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | claimed |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| EP-1863820-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | Nycomed GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100255-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | NYCOMED GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | RAB9A 4475/4885RIPK1 4446/4885BRD4 85/4885 |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | RAB9A 2427/4885RIPK1 4483/4885BRD4 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.